Granite Point Capital Management, L.P. Cellectis S.A. Transaction History

Granite Point Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$8.21 - $21.02 $82,100 - $210,200	-10,000 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$9.73 - $19.31 $97,300 - $193,100	10,000 New	10,000 $171,000
Q1 2018 May 15, 2018	SELL	$27.78 - $35.19 $1.39 Million - $1.76 Million	-50,000 Closed	0 $0
Q4 2017 Feb 08, 2018	BUY	$23.33 - $35.01 $1.17 Million - $1.75 Million	50,000	50,000 $1.46 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.